These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 11363641)
1. Throw down your crutches and walk. Gonslaves G GMHC Treat Issues; 1996; 10(6/7):26-7. PubMed ID: 11363641 [TBL] [Abstract][Full Text] [Related]
2. New AIDS drugs, reduce viral load, but aren't a cure. AIDS Policy Law; 1996 Jul; 11(13):1, 10-1. PubMed ID: 11363661 [TBL] [Abstract][Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
6. FDA approves first new class of HIV drugs. Food and Drug Administration. AIDS Alert; 1996 Aug; 11(8):89. PubMed ID: 11363655 [TBL] [Abstract][Full Text] [Related]
7. Breakthroughs in HIV treatment not yet embraced by clinicians. AIDS Alert; 1996 Aug; 11(8):85-8. PubMed ID: 11363653 [TBL] [Abstract][Full Text] [Related]
8. [New therapy for AIDS: a double-edged sword]. Foreman M Sidahora; 1996; ():38-9. PubMed ID: 11364382 [TBL] [Abstract][Full Text] [Related]
9. [A further option in PI therapy. Approval of a new protease inhibitor in the USA]. MMW Fortschr Med; 2005 Apr; 147 Spec No 1():30. PubMed ID: 16385868 [No Abstract] [Full Text] [Related]
10. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083 [TBL] [Abstract][Full Text] [Related]
12. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. Youle M J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281 [TBL] [Abstract][Full Text] [Related]
13. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718 [TBL] [Abstract][Full Text] [Related]
14. How far can you knock down HIV? An interview with David D. Ho, MD. Interview by Mark Mascolini. Ho DD J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):40-4. PubMed ID: 11364429 [TBL] [Abstract][Full Text] [Related]
15. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM; Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093 [TBL] [Abstract][Full Text] [Related]
16. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]. Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F; Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377 [TBL] [Abstract][Full Text] [Related]